Skip to content

Klebsiella antibiogram software for Klebsiella pneumoniae susceptibility by unit, source and breakpoint year

Klebsiella pneumoniae is the organism where breakpoint changes, ESBL production and unit differences pile on top of each other. Here is what a Klebsiella antibiogram has to show, which CLSI revisions move its numbers, and what each way of building it costs.

8 min read

Antibiogram Builder
Synthetic sample dataset
Parsed in this browser, never uploaded.

under 40 40 to 59 60 to 74 75 to 89 90 and over n<30, below the reporting threshold n/t, not tested on this panel

A Klebsiella antibiogram shows, for first Klebsiella pneumoniae isolates per patient, the percent susceptible to ceftriaxone, cefepime, piperacillin-tazobactam, the carbapenems, the fluoroquinolones, the aminoglycosides and the urinary agents, with the isolate count beside each cell. To be useful for empiric therapy it needs three cuts most annual reports skip: the ICU apart from the wards, urine apart from blood, and the ESBL share. It also needs to say which CLSI breakpoint version produced each year, because four revisions since 2010 have moved Klebsiella percentages without any change in the bacteria.

This article is for the stewardship pharmacist, infectious diseases physician or microbiology supervisor who has to defend the hospital's gram-negative empiric guidance and is tired of rebuilding the Klebsiella row in a spreadsheet. Antimicrobe builds the full table from a lab CSV with no interface, from $249 a month on the Lab plan, and the unit and quarterly cuts are on the Stewardship plan at $749 a month.

What a Klebsiella antibiogram has to show

Klebsiella pneumoniae is the second most common gram-negative in most US hospital antibiograms after Escherichia coli, and it is the one where a single house-wide line hides the most. Urine isolates from the emergency department and nursing home admissions dominate the count, while bloodstream and respiratory isolates from the ICU are fewer and more resistant. The house figure ends up describing the outpatient urine population, and the ICU prescriber reads it for a ventilated patient.

Species handling matters too. Klebsiella oxytoca belongs in its own row. Klebsiella aerogenes, renamed from Enterobacter aerogenes in 2017, carries a chromosomal AmpC that can switch on during third generation cephalosporin therapy, so it should never be pooled with K. pneumoniae on the ceftriaxone line. And ampicillin should not appear for any Klebsiella at all, because the organism is intrinsically resistant to it.

  • K. pneumoniae, K. oxytoca and K. aerogenes as separate rows, with intrinsic ampicillin resistance suppressed
  • First isolate per patient per period, with the rule printed on the report
  • Blood, urine and respiratory sources split where the counts allow
  • ICU apart from the wards, with any cell under 30 isolates shown as a count
  • ESBL and carbapenem-resistant share by quarter, from the same dataset

CLSI breakpoint changes that move Klebsiella numbers

Enterobacterales have had more breakpoint revisions than any other group since 2010, and a hospital comparing its 2018 and 2026 Klebsiella rows is often comparing two definitions. A lab that changes its instrument rules in the middle of a year produces an annual line that mixes both. The table below lists the revisions that move K. pneumoniae percentages the most.

If your instrument reports MICs, the year can be re-interpreted under one version so the trend is honest. Antimicrobe records which version produced each table and can re-run a year of MIC data under the current CLSI or EUCAST rules, described on CLSI and EUCAST breakpoints. The current values are published in CLSI M100.

Main CLSI M100 revisions for Enterobacterales. Check the current edition for exact values before you change local rules.
Drug group Revision Effect on a Klebsiella antibiogram
Ceftriaxone, cefotaxime, ceftazidime, aztreonam Lowered in 2010 (ceftriaxone susceptible at 1 mg/L or less) ESBL producers no longer test susceptible, so ceftriaxone percentages fell
Imipenem, meropenem, ertapenem Lowered in 2010, ertapenem adjusted again in 2012 Some carbapenemase producers moved from S to I or R
Cefazolin Revised in 2010 and 2011, urinary surrogate breakpoint added in 2016 Urine and systemic cefazolin need separate rows
Ciprofloxacin, levofloxacin Lowered in 2019 (ciprofloxacin susceptible at 0.25 mg/L or less) Fluoroquinolone percentages dropped by several points at many hospitals
Piperacillin-tazobactam Lowered in 2022, with a susceptible dose dependent category Isolates at 16 mg/L moved out of the susceptible column
Amikacin, gentamicin, tobramycin Lowered in 2023 Aminoglycoside percentages fell slightly, most for amikacin

A worked example from a 300 bed hospital

Take 520 K. pneumoniae results in a year. After the first isolate rule, 388 patients remain. Hospital-wide, 340 of 388 are ceftriaxone susceptible, 87.6 percent, and 48 isolates, 12.4 percent, are ESBL producers. Piperacillin-tazobactam looks like 352 of 388, 90.7 percent, under the pre-2022 breakpoint, and 331 of 388, 85.3 percent, when the same MICs are re-read under the current one. That five point drop is a rule change, and the committee should hear it as one.

Filter to the medical and surgical ICUs and 64 isolates remain, of which 49 are ceftriaxone susceptible, 76.6 percent, more than ten points below the house line. Filter to urine and 241 isolates remain, and the cefazolin urinary surrogate reads 205 of 241, 85.1 percent, which supports cefazolin for uncomplicated cystitis while the ICU numbers argue for a broader empiric choice in sepsis. All of this comes from one export. These numbers are illustrative arithmetic, not data from a customer.

Ways to build a Klebsiella antibiogram compared

WHONET is the honest free option and handles Klebsiella well if someone on staff knows it. The cost is the learning curve and the hours each year. Instrument reports are cheap but often stuck on the breakpoint version the instrument used that year, which is exactly the problem a Klebsiella trend runs into. Surveillance platforms do far more than an antibiogram, and their patient-level alerts are compared in our review of bug-drug mismatch software.

For that comparison see bug-drug mismatch software compared, and for the full set of antibiogram routes see best antibiogram software for hospitals.

Each route described from its maker's public material. Antimicrobe from its pricing page.
Route Species and source split Breakpoint re-run Who does the work Cost
Excel or Google Sheets Manual filters Manual, rarely done Lab analyst or pharmacist, days per year Staff time
WHONET (WHO) Yes, with training Yes, from MICs Trained lab user Free software, staff time
Instrument or LIS report Varies by vendor Usually only the version loaded that year Lab, with vendor support Included in the contract
Clinical surveillance platform Yes Varies Platform team after interfaces Quoted, usually six figures a year
Antimicrobe Automatic from organism and source columns Yes, CLSI or EUCAST Pharmacist or lab, one upload $249 a month Lab, $749 Stewardship

ESBL and carbapenem-resistant Klebsiella

Most hospitals now want the ESBL share and the carbapenem-resistant count for Klebsiella every quarter, not once a year. The CDC lists ESBL-producing Enterobacterales as a serious threat and carbapenem-resistant Enterobacterales as an urgent one, and K. pneumoniae is the species most often behind KPC in the US. A quarterly line is short, so the counts are small and need the same 30 isolate discipline as the annual table: show the count, not a percentage built on eleven isolates.

Antimicrobe flags ESBL from the lab's own marker or from the cephalosporin pattern, and keeps the CRE count separate. The dedicated pages are ESBL antibiogram software and carbapenem-resistant organisms reporting, and the CDC threat estimates are in its antimicrobial resistance threats report.

Can a small hospital report Klebsiella on its own?

Usually for the whole house, often not for a unit. A 100 bed hospital may see 60 to 100 first K. pneumoniae isolates a year, enough for a house-wide row but not for an ICU row. Pool two or three years for the unit cut, and say on the report that you did. In nursing homes the problem is sharper: in a study of 231 Georgia skilled nursing facilities, only about 1 in 10 had enough K. pneumoniae urine isolates in one year to meet the 30 isolate guideline.

Pooling rules for small facilities are on critical access hospital antibiogram, the urine table on UTI antibiotic resistance rates, and the gram-positive counterpart on Enterococcus antibiogram software.

How much does Klebsiella antibiogram software cost?

Klebsiella is not sold as a separate product. It is a row in the cumulative antibiogram, so the price is the price of the antibiogram route. WHONET is free and costs staff time. Surveillance platforms are quoted per organization. Antimicrobe is $249 a month for one facility on the Lab plan, bought by card, and $749 a month on Stewardship for unit cuts, quarterly trends and ESBL and CRE counts across three facilities. Annual billing halves the monthly price.

Plans are on the pricing page, and the full cost comparison by route is in antibiogram software cost.

Questions to settle before the next report

  • Does our lab identify K. aerogenes and K. oxytoca separately, and does the export carry it
  • Which CLSI version did the instrument use in each year we want to trend
  • Do we report cefazolin with the urinary surrogate breakpoint, the systemic one, or both
  • How many first K. pneumoniae isolates did each ICU have last year
  • Who signs off the ESBL definition used on the quarterly report

Related on this site: ESBL antibiogram software, ICU antibiogram software, hospital antibiogram software.

Next step

Build the Klebsiella table from your lab export, from $249 a month

Set the filters, watch the numbers move, and read the rules that produced them. The builder is open on the homepage, with no account and no upload.

Your file is parsed in your browser and never uploaded. No card required.